Cargando…

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Pasireotide has a broader somatostatin receptor binding profile than other somatostatin analogues. A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly. An extension to this trial assessed the long-term efficacy and safety of pasireotide. This study was an o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petersenn, Stephan, Farrall, Andrew J., Block, Christophe, Melmed, Shlomo, Schopohl, Jochen, Caron, Philippe, Cuneo, Ross, Kleinberg, David, Colao, Annamaria, Ruffin, Matthieu, Hermosillo Reséndiz, Karina, Hughes, Gareth, Hu, Ke, Barkan, Ariel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942632/ https://www.ncbi.nlm.nih.gov/pubmed/23529827 http://dx.doi.org/10.1007/s11102-013-0478-0

Ejemplares similares

Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
por: Petersenn, Stephan, et al.
Publicado: (2013)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
por: Bronstein, Marcello D., et al.
Publicado: (2016)

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
por: Sheppard, Michael, et al.
Publicado: (2014)

Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
por: Sheppard, Michael, et al.
Publicado: (2015)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States
por: Fleseriu, Maria, et al.
Publicado: (2022)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly
por: Silverstein, Julie M.
Publicado: (2016)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

Molecular targets in acromegaly
por: Labadzhyan, Artak, et al.
Publicado: (2022)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
por: Puglisi, Soraya, et al.
Publicado: (2020)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study
por: Wolin, Edward M., et al.
Publicado: (2013)

Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study
por: Giustina, Andrea, et al.
Publicado: (2019)

Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis
por: Fleseriu, Maria, et al.
Publicado: (2023)

Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
por: Yao, James C, et al.
Publicado: (2017)

The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome
por: Klibanski, Anne, et al.
Publicado: (2009)

Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
por: Boscaro, M., et al.
Publicado: (2013)

Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
por: Petersenn, S., et al.
Publicado: (2017)

Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
por: Marques, Nelma Veronica, et al.
Publicado: (2023)

THU061 Treatment Patterns In Acromegaly: Analysis Of Real-World US Insurance Claims From The MarketScan(®) Database
por: Fleseriu, Maria, et al.
Publicado: (2023)

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(®) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
por: Melmed, Shlomo, et al.
Publicado: (2009)

Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly
por: Amarawardena, W K M G, et al.
Publicado: (2017)

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study
por: Gadelha, Mônica, et al.
Publicado: (2019)

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
por: Lasolle, Hélène, et al.
Publicado: (2019)

Successful Therapy Using Pasireotide Long-acting Release for Cushing's Disease Merged with Biochemical Acromegaly
por: Fukunaga, Kensaku, et al.
Publicado: (2020)

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence study
por: Manetti, Luca, et al.
Publicado: (2019)

SAGIT(®): clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study
por: Giustina, Andrea, et al.
Publicado: (2015)

Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2021)

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012)

Clinical, quality of life, and economic value of acromegaly disease control
por: Ben-Shlomo, A., et al.
Publicado: (2011)

Editorial: Health-Related Complications of Acromegaly
por: Bolanowski, Marek, et al.
Publicado: (2020)

Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
por: Wolf, Peter, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dad7hbm9mipfdteou8cs8403iq